×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!
   

Playing Defense In A Riskier Commercial Environment For Cancer Drugs

August 23, 2017

Cancer drugs are under fire across the globe for their putatively high prices and modest benefits. As probability of clinical success has risen, the probability of commercial success has fallen. What defensive strategies can you take to mitigate commercial risks?

Defensive development strategies for cancer drugs can help manage the substantial and increasing commercial risk in today’s marketplace. To develop defensively, three steps are essential: 

 1.  Make sure the sum of your market model is made up of accurate parts

2.  Embed economically relevant endpoints in clinical trials

3.  Learn from the past

Business as usual is not an option for developers trying to navigate the still-promising but increasingly crowded and complex cancer marketplace. Gaining a thorough understanding of market opportunities, running trials with economically quantifiable endpoints, and studying the market access track record of both successful and unsuccessful cancer drugs are three ways to manage and mitigate commercial risks more effectively

Previous Flipbook
Accelerated Pathways: Global Opportunities and Challenges For Innovators
Accelerated Pathways: Global Opportunities and Challenges For Innovators

Find out more about Accelerated Pathways here!

Next Flipbook
Global Forum: Driving Ideas to Action
Global Forum: Driving Ideas to Action

Learn more about Accelerated Pathways here!